The Australian sharemarket closed higher on Friday after Wall Street rallied overnight,as investors hope the US Federal Reserve may finally be done with raising interest rates.
Scientists are adapting mRNA technology used for COVID-19 vaccinations to combat deadly illnesses,including cancer.
Moderna will lodge approval applications for a new vaccine for RSV that could be on the market as soon as next year in a big step forward in its pipeline outside of COVID.
Less than two years after launching its COVID vaccine to the world,Moderna is cashed up,and ready to expand its market hold with Australia as a key base.
BioNTech is one of the world’s two leading mRNA companies,and it has just announced it will open a research and development hub in Melbourne.
Moderna chief Stephane Bancel is thinking well beyond its current COVID vaccines when it comes to the Australian market.
Novavax COVID-19 vaccines procured by the federal government are expected to be thrown out after expiring before they could be used.
The new polling suggests Australians are becoming less spooked by the pandemic,but the exclusive results don’t suggest we have quite reached ambivalence.
Both Moderna and Pfizer have made tens of billions of dollars in coronavirus vaccine sales around the world.
The facility at Monash’s Clayton campus will be the first site producing mRNA vaccines in the southern hemisphere,and is soon expected to be making 100 million doses each year.
Australians aged five to 15 have fewer side effects - such as a sore arm,fatigue,headaches and muscle pain - after their vaccinations than those reported in clinical trials.